eNeura Overview
- Year Founded
-
2000
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
eNeura General Information
Description
Developer of transcranial magnetic stimulation devices designed to treat migraines. The company's device helps pre-empt migraines to reduce the severity and duration of episodes, decrease the frequency of attacks, and delivers single low-frequency electromagnetic fields that pass painlessly through bone and tissue, signaling the brain to calm hyperactive nerves and return to a natural state, a process known as Single Pulse Transcranial Magnetic Stimulation (sTMS) allows home use and delivers non-invasive pulses to calm hyperactive nerves, enabling patients to get effective treatment for their painful attacks.
Contact Information
Website
www.eneura.comCorporate Office
- 101 West Dickman Street
- Suite 900
- Baltimore, MD 21230
- United States
Corporate Office
- 101 West Dickman Street
- Suite 900
- Baltimore, MD 21230
- United States
eNeura Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Secondary Transaction - Private | 01-Apr-2022 | Completed | Pre-Clinical Trials | |||
| 13. Later Stage VC (Series A) | 21-Feb-2020 | Completed | Pre-Clinical Trials | |||
| 12. Later Stage VC (Series E) | 09-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 11. Later Stage VC (Series D) | 21-Nov-2018 | Completed | Pre-Clinical Trials | |||
| 10. Merger/Acquisition | 31-Mar-2015 | Cancelled | Pre-Clinical Trials | |||
| 9. Later Stage VC (Series B) | 28-Aug-2014 | Completed | Pre-Clinical Trials | |||
| 8. Later Stage VC (Series A3) | 02-Jan-2014 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series A2) | 01-Oct-2013 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC (Series A1) | 19-Aug-2013 | $3.23M | $24.3M | Completed | Pre-Clinical Trials | |
| 5. Later Stage VC (Series A) | 08-Nov-2012 | $1M | $21.1M | Completed | Pre-Clinical Trials |
eNeura Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
eNeura Comparisons
Industry
Financing
Details
eNeura Competitors (7)
One of eNeura’s 7 competitors is CEFALY, a Private Equity-Backed company based in Seraing, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CEFALY | Private Equity-Backed | Seraing, Belgium | ||||
| Newronika | Venture Capital-Backed | Milan, Italy | ||||
| Neuronetics | Formerly VC-backed | Malvern, PA | ||||
| Flow Neuroscience | Venture Capital-Backed | Malmö, Sweden | ||||
| Theranica | Venture Capital-Backed | Netanya, Israel |
eNeura Patents
eNeura Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2015357539-A1 | Methods and systems for preventative migraine headache treatment | Inactive | 05-Dec-2014 | ||
| AU-2022202328-A1 | Methods and systems for preventative migraine headache treatment | Inactive | 05-Dec-2014 | ||
| US-20160158571-A1 | Methods and systems for preventative migraine headache treatment | Inactive | 05-Dec-2014 | ||
| US-9526912-B1 | Transcranial magnetic stimulation device for the treatment of migraine headaches | Active | 13-May-2014 | ||
| US-9724533-B1 | Transcranial magnetic stimulation device for the treatment of migraine headaches | Active | 13-May-2014 | A61N2/008 |
eNeura Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
eNeura Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abell Foundation | Not-For-Profit Venture Capital | Minority | ||
| Catalio Capital Management | Venture Capital | Minority | ||
| David Oros | Angel (individual) | Minority | ||
| Marc Blum | Angel (individual) | Minority | ||
| The Fischell family | Family Office | Minority |
eNeura FAQs
-
When was eNeura founded?
eNeura was founded in 2000.
-
Where is eNeura headquartered?
eNeura is headquartered in Baltimore, MD.
-
What is the size of eNeura?
eNeura has 22 total employees.
-
What industry is eNeura in?
eNeura’s primary industry is Therapeutic Devices.
-
Is eNeura a private or public company?
eNeura is a Private company.
-
What is eNeura’s current revenue?
The current revenue for eNeura is .
-
How much funding has eNeura raised over time?
eNeura has raised $63.3M.
-
Who are eNeura’s investors?
Abell Foundation, Catalio Capital Management, David Oros, Marc Blum, and The Fischell family are 5 of 8 investors who have invested in eNeura.
-
Who are eNeura’s competitors?
CEFALY, Newronika, Neuronetics, Flow Neuroscience, and Theranica are some of the 7 competitors of eNeura.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
